No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

USA: In a significant advancement for the treatment of severe alopecia areata (AA), long-term data from two phase III ...

Lilly and Incyte's already-marketed JAK inhibitor Olumiant (baricitinib) is currently in the lead among drugs for alopecia areata, with a filing due in the second half of this year after two ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

Maryanne Senna, MD, assistant professor of dermatology at Harvard Medical School, discusses the results of the case and the impact JAK inhibitors have had on the treatment of alopecia areata ...

Adding narrowband ultraviolet B (UVB) phototherapy to oral treatment with ritlecitinib (Litfulo) enhanced repigmentation in ...

Hair is more than a style statement; it’s a mirror of our health. For both men and women, hair-related challenges – ranging ...